Search

file (14) (1)

Investor Overview

Investor Overview

HOMEInvestor Overview

Read More

2025.Jun.06

News

OBI Pharma Enters ADC Collaboration with TegMine Therapeutics utilizing GlycOBI® and TegMiner™ Enabling Technologies

2025.May.01

News

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-902, a Trop-2 Targeting ADC

2025.Apr.29

News

OBI Pharma Unveils New ThiOBI® and HYPrOBI™ Platforms
Showcasing Strong ADC Development Capabilities and Captivating Attention at AACR

Read More

2025.Jun.06

Announcement

OBI's GlycOBI has attracted an international collaborator, TegMine Therapeutics, for the co-development of novel Antibody-Drug Conjugates

2025.May.20

Announcement

Announcement on behalf of OBIGEN of resolution to lift the non-competition restrictions for directors

2025.May.20

Announcement

Announcement on behalf of OBIGEN of important resolutions of 2025 Annual Shareholders’ meeting and accumulated losses amounting to 50% of paid-in capital

2023 Annual Report

Learn how we created value in 2023 and worked to pursue our purpose of enabling a healthier world.

Download PDF
Read More

Featured
Presentation

2024 Investors' Meeting - Innovation and Optimism

Download PDFAnnual Report

Read More

2024 Annual Shareholders’ Meeting

  • 2024.Jun.17 at 09:00 AM
  • Masterlink Securities Education and Training Center

Governance

Read More

Corporate
Overview​

Board of
Directors​

Special ​
Committee​

Integrity​

Internal
Audit​

Governance
Document​

Investor Relations

Contact